Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Theolytics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Theolytics
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
Innovation Building Roosevelt Drive Oxford England OX3 7FZ
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The proceeds from the financing round further strengthen the company’s position as it advances its lead oncolytic adenovirus, THEO-260, a next-generation oncolytic adenovirus, into clinical trials in ovarian cancer.


Lead Product(s): THEO-260

Therapeutic Area: Oncology Product Name: THEO-260

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Sound Bioventures

Deal Size: $24.5 million Upfront Cash: Undisclosed

Deal Type: Financing April 17, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

THEO-260 is a new oncolytic virus in development that is intrinsically capable of targeted killing of both cancer cells and cancer associated fibroblasts (CAFs).


Lead Product(s): THEO-260

Therapeutic Area: Oncology Product Name: THEO-260

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company's unique technology platforms.


Lead Product(s): Oncolytic Viral Therapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: M Ventures

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Series A Financing July 08, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The financing will be used to progress the company’s Oncolytic viral therapies towards human clinical trials.


Lead Product(s): Oncolytic viral therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: Epidarex Capital

Deal Size: $6.8 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY